DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Infant

Conditions

Infant, Healthy

Trial Timeline

Sep 1, 2006 → Jul 1, 2008

NCT ID

NCT00355654

About DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV

DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV is a phase 3 stage product being developed by Sanofi for Infant. The current trial status is completed. This product is registered under clinical trial identifier NCT00355654. Target conditions include Infant, Healthy.

What happened to similar drugs?

4 of 13 similar drugs in Infant were approved

Approved (4) Terminated (4) Active (8)

✅Placebo + CisaprideJohnson & JohnsonApproved

✅alglucosidase alfa + alglucosidase alfaSanofiApproved

✅Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved

✅VigabatrinLundbeckApproved

🔄somatropinEli LillyPhase 3

🔄RotaTeq (V260) + IPVMerckPhase 3

❌Recombinant human growth hormone (r-hGH)MerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00355654	Phase 3	Completed	Sep 1, 2006	Jul 1, 2008	Infant

Competing Products

20 competing products in Infant

See all competitors

Product	Company	Stage	Hype Score
SPIKEVAX	Moderna	Preclinical	0
TSHA-101	Taysha Gene Therapies	Phase 1/2	30
somatropin	Eli Lilly	Phase 3	40
Placebo + Cisapride	Johnson & Johnson	Approved	35
RotaTeq (V260) + IPV	Merck	Phase 3	40
recombinant somatropin	Merck	Pre-clinical	26
Recombinant human growth hormone (r-hGH)	Merck	Phase 3	32
MAS825 + Placebo	Novartis	Phase 2	39
epoetin beta + epoetin beta	Roche	Pre-clinical	26
Genotropin (PN-180,307) Somatropin + Control-no treatment	Pfizer	Phase 3	40
Prevenar (13v)	Pfizer	Pre-clinical	26
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	35
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	35
alglucosidase alfa + alglucosidase alfa	Sanofi	Approved	35
Myozyme	Sanofi	Phase 2	35
Bacillus Clausii Multi ATB Resist + Placebo	Sanofi	Approved	43
Radiprodil	UCB	Phase 2	27
Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care	Bayer	Pre-clinical	23
Sabril®	Lundbeck	Pre-clinical	23
Vigabatrin	Lundbeck	Approved	32